Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitroglycerin versus labetalol for blood pressure control in intracerebral hemorrhage
IRCT20171221037983N2Phase 3Completed
- Sponsor
- Urmia University of Medical Sciences
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of labetalol and nitroglycerin in intracerebral hemorrhage (ICH) and hypertension (HTN) (2 arms), sponsored by Urmia University of Medical Sciences. Primary endpoints: Systolic blood pressure and Diastolic blood pressure. Started Mar 2017; status: completed.
02
Drugs
labetalolnitroglycerin
03
Conditions
intracerebral hemorrhage (ICH)hypertension (HTN)
Beyond the preview
Go deeper on IRCT20171221037983N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20171221037983N2.